Foundayo Just Got FDA approval. Here’s what it actually means.
The new oral GLP-1 pills: Foundayo, Wegovy, and what they actually mean.
A measured clinical read on the two new oral GLP-1 medications approved this spring — what the data actually shows, when an oral pill makes sense versus an injectable, and how we'll think about them for our weight loss patients.
On April 1, 2026, the FDA approved Foundayo (orforglipron) — the first oral small-molecule GLP-1 receptor agonist for chronic weight management. Just over a month later, on May 7, the FDA approved a daily-pill version of Wegovy (oral semaglutide). The era of injectable-only GLP-1s is officially over. Most of the early coverage has been breathless. Ours won't be. Here's what the data actually shows for both drugs, when oral makes sense, when it doesn't, and what we'll be telling our weight loss patients when they ask.
We've spent the past few years treating weight loss patients with semaglutide and tirzepatide — the injectable GLP-1 medications that have reshaped the conversation around obesity treatment. Those drugs work, and they work well. The arrival of two oral options doesn't change that. But it does add meaningful new choices, particularly for specific kinds of patients.
This article is a real read on what these drugs are, what they aren't, and how we'll be using them in our practice. We're not endorsing them, and we're not dismissing them. We're treating them the way we treat every new tool — with measured clinical evaluation.
What Foundayo actually is.
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist made by Eli Lilly. It works through the same hormonal pathway as Wegovy (semaglutide) and Zepbound (tirzepatide) — mimicking glucagon-like peptide-1 to reduce appetite, slow stomach emptying, and improve blood sugar regulation.
What makes it different is its molecular structure. Most GLP-1 medications, including injectable Wegovy and the newly approved Wegovy pill, are peptides — long protein chains that have to either be injected or, in oral form, taken with strict fasting and water restrictions to be absorbed. Foundayo is a small-molecule, non-peptide drug. It's structurally simpler, more stable, and absorbs reliably without fasting.
The practical implication: you take a pill once a day, any time of day, with or without food. No 30-minute fasting window. No water restrictions. No injections.
What the Wegovy pill actually is.
The Wegovy pill is a daily oral version of semaglutide — the same active ingredient that's been used in injectable Wegovy and Ozempic for years. Manufactured by Novo Nordisk and approved by the FDA on May 7, 2026, it gives patients a needle-free option using the most studied GLP-1 active ingredient on the market.
Critically, the Wegovy pill uses a different absorption-enhancing formulation than the older oral semaglutide product (Rybelsus, approved for type 2 diabetes). This new formulation produces consistent enough absorption to drive weight loss outcomes comparable to the injectable form — something the older formulation couldn't reliably do.
The trial data from the OASIS 4 study showed weight loss outcomes broadly comparable to injectable Wegovy. According to Novo Nordisk's announcement, the company is positioning the pill as offering weight loss roughly equivalent to the injection — a meaningful claim if it holds up in real-world use.
Important practical detail
The Wegovy pill, like its predecessor Rybelsus, requires being taken in the morning on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before eating, drinking, or taking other medications. This is fundamentally different from Foundayo, which has no food or water restrictions. The fasting requirement is a real adherence challenge for some patients.
What the Foundayo data shows.
The pivotal trial supporting Foundayo's FDA approval was ATTAIN-1, published in the New England Journal of Medicine. It enrolled 3,127 adults with obesity (or overweight with a weight-related condition, no diabetes) and randomized them to placebo or one of three doses of orforglipron over 72 weeks.
The results, in plain English:
- Highest dose (17.2 mg): ~11.1-12.4% body weight loss, or roughly 25-27 pounds for someone starting around 225 lbs
- Mid dose (9 mg): ~8.3% body weight loss, or roughly 19 pounds
- Lower dose (5.5 mg): ~7.4% body weight loss, or roughly 17 pounds
- Placebo: ~2.1% (essentially diet/exercise alone)
A separate trial in patients with type 2 diabetes (ATTAIN-2) showed slightly lower weight loss (5-9.6% depending on dose) along with meaningful improvements in A1C, blood pressure, cholesterol, and waist circumference — the cardiometabolic markers that drive long-term health outcomes.
For context: this is real, meaningful weight loss. It's not as dramatic as the 15% average we typically see with injectable Wegovy or the 20%+ with Zepbound at maximum doses, but it's substantial — and it comes with meaningful improvements in metabolic health markers.
How they all compare.
The honest comparison most people want to see, now with both oral options on the market:
| Foundayo | Wegovy Pill | Wegovy Injection | Zepbound | |
|---|---|---|---|---|
| Form | Daily pill | Daily pill | Weekly injection | Weekly injection |
| Active drug | Orforglipron (small molecule) | Semaglutide (peptide) | Semaglutide (peptide) | Tirzepatide (GLP-1 + GIP) |
| Avg weight loss (max dose) | ~11-12% | Comparable to injection | ~15% | ~20-22% |
| Food/water rules | None | Strict fasting + 4oz water + 30-min wait | (N/A injection) | (N/A injection) |
| Common side effects | GI: nausea, diarrhea | GI: nausea, diarrhea | GI: nausea, diarrhea | GI: nausea, diarrhea |
| Long-term data | 72 weeks | New approval | 5+ years | 3+ years |
The tradeoffs are now clearer. Foundayo is the most convenient pill (no food or water rules) but has somewhat less weight loss than peptide-based alternatives. The Wegovy pill matches injection-level weight loss but requires the same fasting protocol that makes the older Rybelsus difficult for many patients to adhere to. Injectable options remain the gold standard for maximum weight loss, particularly Zepbound's tirzepatide for patients with substantial weight loss goals.
Foundayo vs. Wegovy pill: head to head.
The most useful comparison for patients considering an oral GLP-1 is between the two oral options themselves. Each has clear strengths and meaningful limitations.
Foundayo's advantages.
- No food or water restrictions. Take it any time of day, with or without food. This is a substantial real-world adherence advantage.
- Generally lower cost. Self-pay starts at $149/month; with savings card and commercial insurance, eligible patients may pay as low as $25/month.
- Lower risk of administration errors. Patients don't have to remember to fast or watch the clock.
Wegovy pill's advantages.
- Stronger weight loss potential. Trial data suggests weight loss comparable to injectable Wegovy — potentially 3-4 percentage points more weight loss than Foundayo.
- Longer track record on the active ingredient. Semaglutide has 5+ years of real-world safety data from the injectable form. Orforglipron is brand new.
- Cardiovascular outcomes data on the active ingredient. Injectable semaglutide has demonstrated cardiovascular benefits in large outcomes trials. Whether this translates to the pill form is still being studied, but the active ingredient is the same.
How to think about the choice.
The fasting requirement is the practical fork in the road. If a patient can reliably take a pill first thing in the morning, wait 30 minutes before coffee, food, or other medications, and do so every single day — the Wegovy pill offers more weight loss potential. If those restrictions sound difficult, the gap in real-world results closes considerably; an effective dose taken consistently beats a more potent dose taken erratically.
The honest version
For our patients, the best oral GLP-1 is the one they'll actually take consistently. Foundayo's flexibility is a real advantage for busy patients, parents, shift workers, and anyone whose mornings don't follow a predictable routine. The Wegovy pill's stronger efficacy only matters if patients can adhere to the strict morning protocol.
Who oral GLP-1s are actually right for.
Based on the data and our clinical experience with GLP-1 patients, here's the honest picture of who's likely to do well on either oral option:
An oral GLP-1 is likely a good fit if you:
- Have moderate weight loss goals. If you need to lose 20-40 pounds to reach a healthier body composition, oral options can deliver meaningful results.
- Strongly prefer pills over injections. Some patients can't or won't inject for medical, psychological, or lifestyle reasons. Both Foundayo and Wegovy pill are real options now.
- Are motivated to combine medication with lifestyle change. Trial results assume diet, exercise, and behavioral support. Patients who do all three see the best outcomes.
- Want a more affordable starting point. Oral options are typically less expensive than injectables, especially Foundayo with the Lilly savings card.
- Have type 2 diabetes or metabolic syndrome. Both drugs offer cardiometabolic benefits beyond weight loss.
An oral GLP-1 is probably not the right first choice if you:
- Need to lose 50+ pounds. Injectable Zepbound (tirzepatide) has stronger weight loss in trials and a longer track record for substantial weight reduction.
- Have liver disease or take medications metabolized by the liver. Foundayo is metabolized hepatically with FDA-flagged liver enzyme monitoring. Drug interactions are a real consideration.
- Have already lost meaningful weight on an injectable and want to maintain. If Wegovy injection or Zepbound are working for you, switching to a less potent oral option would likely mean some regain (this is less of an issue switching to the Wegovy pill, more so for Foundayo).
- Cannot reliably adhere to fasting protocols. The Wegovy pill specifically requires morning fasting and water restrictions. Foundayo is a better choice for patients with unpredictable schedules.
The honest version
Most of our weight loss patients won't be switching to an oral option. The injectables are working well for them. But for the patient who's been hesitant to start a GLP-1 because of the injection — both Foundayo and the Wegovy pill open real doors that weren't there a year ago. Which one is right depends on your weight loss goals, lifestyle, and how reliably you can stick to a fasting protocol.
How we'll think about them at Defiance.
New medications don't change our process — they just add options to discuss during the comprehensive evaluation. Here's what hasn't changed and what has:
What stays the same:
- The intake comes first. We don't prescribe weight loss medication based on a 5-minute telehealth visit. Our comprehensive intake includes hormone evaluation, metabolic labs, and a real conversation about what's actually been getting in the way.
- The full picture matters. A patient's testosterone status, thyroid function, perimenopause stage, sleep, stress, and insulin resistance all affect how any GLP-1 will work. We evaluate all of it.
- Lifestyle is non-negotiable. The medication doesn't replace nutrition, resistance training, and behavior change. It supports them.
- Muscle preservation matters. Recent research suggests GLP-1 medications can drive significant lean body mass loss alongside fat loss, particularly with tirzepatide. We pair every GLP-1 patient with resistance training and adequate protein protocols. Neither oral option changes that.
What's new:
- Two oral GLP-1 options join the medication list. When clinically appropriate, we can prescribe either Foundayo or the Wegovy pill as part of a treatment plan.
- Liver monitoring becomes part of the protocol for Foundayo patients. Because Foundayo is metabolized in the liver, we add liver function tests to baseline and follow-up labs for patients on it.
- The conversation about oral vs. injectable becomes more nuanced. It's no longer a single binary decision — it's now a real menu of options based on weight loss goals, lifestyle, cost, and adherence factors.
- Adherence assessment matters more. The Wegovy pill's fasting requirement is a real consideration. We'll ask about morning routines, work schedules, and daily structure before recommending it.
What they cost.
Foundayo
Eli Lilly is launching Foundayo through their direct-to-consumer LillyDirect pharmacy. The published pricing structure:
- Commercial insurance with savings card: as low as $25/month for eligible patients
- Self-pay through LillyDirect: starting at $149/month for the lowest dose, scaling up with higher doses
- Medicare Part D (eligible patients): approximately $50/month beginning July 1, 2026
Wegovy pill
Novo Nordisk's pricing for the Wegovy pill is still being finalized for retail pharmacy launch. Industry analysts expect cash-pay pricing to start around $349/month based on Novo Nordisk's existing oral GLP-1 (Rybelsus) pricing structure, though promotional and savings card pricing may bring this down for eligible patients with commercial insurance.
Real-world insurance coverage will vary significantly between plans. Many commercial plans are still finalizing their coverage policies for both drugs. Some plans will cover one or both. Others won't. Some will require step therapy through other GLP-1 options first.
At Defiance, we work with patients to understand their insurance situation and find the most affordable path. Our medical weight loss program is a cash-pay clinical service — we charge for our clinical time, not for the medication itself, which goes through your pharmacy of choice.
The bigger picture.
The approval of Foundayo in April and the Wegovy pill in May reflects a broader shift in how obesity is being treated. The drug pipeline coming over the next 2-3 years is substantial — multiple new injectable and oral GLP-1 options, some with novel mechanisms (triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously).
What this means for patients is that "GLP-1 therapy" is evolving from a single decision into a real menu of options. Different drugs will work better for different people. The future of weight loss medicine is going to be much more personalized — matching the right drug to the right patient based on their goals, health profile, and preferences.
That's a good thing for patients. It's also a good thing for clinics that take the time to actually understand each patient's situation rather than prescribing based on whatever's most profitable to compound. Defiance has always been a comprehensive intake, real evaluation, real plan kind of practice. The expanding GLP-1 landscape just makes that approach more valuable, not less.
Start with a real conversation.
The right weight loss medication depends on your goals, your metabolic profile, your hormonal status, and what's actually been getting in the way. Our comprehensive intake is built to answer those questions properly. Available in Centennial, Alamosa, and via Colorado-wide telehealth.
Oral GLP-1 FAQs.
What's the difference between Foundayo and the Wegovy pill?
Both are daily oral GLP-1 medications, but they're structurally different drugs. Foundayo (orforglipron) is a small-molecule, non-peptide drug taken at any time of day with no food or water restrictions. The Wegovy pill (oral semaglutide) is a peptide drug that requires morning fasting, no more than 4 ounces of water, and a 30-minute wait before eating. Wegovy pill offers stronger weight loss potential, but Foundayo is more convenient for daily life.
Is the Wegovy pill the same as Rybelsus?
Both contain oral semaglutide, but the Wegovy pill uses a different absorption-enhancing formulation specifically optimized for weight loss outcomes. Rybelsus is FDA-approved only for type 2 diabetes; the Wegovy pill is the first oral semaglutide approved specifically for chronic weight management.
Is Foundayo the same as Wegovy or Ozempic?
No. All are GLP-1 receptor agonists, but they're structurally different drugs. Wegovy and Ozempic both contain semaglutide, a peptide-based GLP-1. Foundayo contains orforglipron, a small-molecule (non-peptide) GLP-1. They work through the same hormonal pathway but have different effectiveness, dosing, and tradeoffs.
How much weight will I lose on Foundayo?
In the ATTAIN-1 trial, patients on the highest dose (17.2 mg) lost an average of 11-12% of their body weight over 72 weeks — roughly 25-27 pounds for someone starting around 225 lbs. Lower doses produced proportionally less weight loss. Individual results vary significantly based on starting weight, lifestyle factors, and adherence to diet and exercise recommendations.
How much weight will I lose on the Wegovy pill?
Trial data from OASIS 4 showed weight loss outcomes broadly comparable to injectable Wegovy, which produces approximately 15% body weight loss on average at maximum dose over 68 weeks. Real-world results will likely depend significantly on patient adherence to the morning fasting protocol.
Why is Foundayo's weight loss less than Wegovy or Zepbound?
Honestly, we don't fully know yet. Foundayo's small-molecule structure is novel, and it may simply be a less potent activator of the GLP-1 receptor than peptide-based versions. It's also worth noting that Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors — a dual mechanism that drives stronger weight loss than GLP-1 alone. Future research will clarify the exact reasons.
Can I switch from injectable to oral GLP-1?
It's possible, but most patients who are doing well on injectable GLP-1s will see some weight regain when switching. The Wegovy pill may produce less regain than Foundayo since it contains the same active ingredient as the injection. We'd discuss your specific situation during a follow-up appointment. If you're switching for cost, convenience, or side effect reasons — those are valid considerations, but the tradeoff in weight loss should be part of the conversation.
Do oral GLP-1s have side effects?
Yes, similar to other GLP-1 medications — primarily gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach pain. These are typically worse during dose escalation and improve over time. Foundayo is also metabolized in the liver, which means there's a risk of elevated liver enzymes and potential drug interactions with other medications processed by liver enzymes. We add liver function monitoring to baseline and follow-up labs for Foundayo patients.
Do I have to fast or skip water with these pills?
Foundayo: No. Take it any time of day, with or without food, with no water restrictions. Wegovy pill: Yes. Must be taken in the morning on an empty stomach with no more than 4 ounces of water, with a 30-minute wait before eating, drinking, or taking other medications. This adherence difference is one of the main practical considerations when choosing between the two.
How does Foundayo dosing work?
Foundayo follows a slow-titration schedule similar to other GLP-1s. You start at 0.8 mg once daily, then increase the dose every 30 days through 2.5, 5.5, 9, 14.5, and finally 17.2 mg if needed and tolerated. The gradual increase helps minimize gastrointestinal side effects.
Will my insurance cover these pills?
Coverage varies significantly by plan. Many commercial plans are still finalizing their formularies for both drugs. Some will cover one or both. Some will require step therapy. Lilly offers a savings card that may bring eligible commercial-insurance patients to as low as $25/month for Foundayo. Self-pay through LillyDirect starts at $149/month. Wegovy pill cash-pay pricing is expected to be higher (likely starting around $349/month) but with potential savings programs through Novo Nordisk. We help patients navigate insurance during the consultation.
Are oral GLP-1s HSA/FSA eligible?
Generally yes, when prescribed for an FDA-approved indication. The clinical visit fees and the medications themselves are typically eligible expenses. Confirm with your specific plan administrator.
Can I take an oral GLP-1 for cosmetic weight loss?
No. Both Foundayo and the Wegovy pill are FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related medical condition. They are not approved or appropriate for cosmetic weight loss. We follow the FDA-approved indications strictly.
How is Defiance different from telehealth-only GLP-1 clinics?
We're a comprehensive medical wellness practice with hormone clinicians on staff, not a single-medication telehealth shop. Our weight loss program includes a full hormonal evaluation, metabolic labs, real clinical time (75 minutes for the comprehensive intake), and ongoing monitoring including muscle mass and body composition. Most weight challenges are downstream of broader hormonal or metabolic factors that single-drug clinics aren't set up to address.
How do I get started?
Book a comprehensive intake. We'll do a full evaluation — history, hormone labs, metabolic markers, body composition — and figure out together whether GLP-1 therapy is right for you, and if so, which option (Foundayo, Wegovy pill, Wegovy injection, Zepbound, or another approach) makes the most sense. Available at our Centennial and Alamosa clinics, with telehealth available throughout Colorado.
Foundayo (orforglipron) is a prescription medication FDA-approved on April 1, 2026. The Wegovy pill (oral semaglutide) is a prescription medication FDA-approved on May 7, 2026. Both are approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related medical condition. Individual results vary. This article is for educational purposes only and does not constitute medical advice. Consult with a qualified medical provider before beginning any treatment. Defiance Health is a cash-pay medical wellness clinic with locations in Centennial and Alamosa, Colorado. Foundayo is a registered trademark of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk.